Edesa Biotech price to sales ratio EDSA

Market value divided by revenue over the last twelve months, since 2016.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 184×; Jan 2021
10-year median: 33.9×
10-year range: 11.8× to 194×
Peer median: 0.4×

Edesa Biotech's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Jan 2021, at 184×.

On the days it had one over the last ten years, its median was 33.9×, from 11.8× in Jun 2019 to 194× in Oct 2019.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2021	184×	155×	185×
2020	136×	25.1×	166×
2019	52.3×	11.8×	194×
2018	23.1×	20.0×	80.7×
2017	37.3×	14.5×	54.4×
2016	16.2×	15.5×	16.2×

Against its peers

Companies in Drug Manufacturers - General nearest Edesa Biotech's size, closest first, today.

Company	Price to sales ratio
EDSAEdesa Biotech	n/m
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
NATRNatures Sunshine Products	0.4×
Peer median	0.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Edesa Biotech

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.